Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 26. Отображено 26.
06-04-2021 дата публикации

4,5-annulated 1,2,4-triazolones

Номер: US0010968216B2

The present invention provides triazolone compounds of general formula (I): in which R1, R2, R3, R4and R5are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.

Подробнее
20-09-2018 дата публикации

COMPOUNDS AND METHODS USEFUL FOR TREATING OR PREVENTING HEMATOLOGICAL CANCERS

Номер: US20180263970A1

The present invention includes methods of treating patients with acute myeloid leukemia across a range of genetic subtypes with DHODH inhibitors, such as 6-fluoro-2-(2′-fluoro-[1,1′-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid). 1. A method of treating or preventing a hematological cancer in a subject in need thereof , the method comprising administering to the subject a therapeutically effective amount of a dihydroorotate dehydrogenase (DHODH) inhibitor , wherein the dihydroorotate inhibitor is selected from the group consisting of 6-fluoro-2-(2′-fluoro-[1 ,1′-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid); 5-methyl-N-[4-(trifluoromethyl) phenyl]-isoxazole-4-carboxamide); and (2Z)-2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]but-2-enamide); or any combinations salts , or solvates thereof; wherein said DHODH inhibitor is administered to the subject with a frequency less than or equal to once every 72 hours.2. The method according to claim 1 , wherein 6-fluoro-2-(2′-fluoro-[1 claim 1 ,1′-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid) or a salt or solvate thereof is administered to the subject with a frequency less than or equal to once every 72 hours.3. The method according to claim 1 , wherein 6-fluoro-2-(2′-fluoro-[1 claim 1 ,1′-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid) or a salt or solvate thereof is administered to the subject with a frequency less than or equal to once every 48 hours.4. The method according to claim 1 , wherein the hematological cancer comprises acute myeloid leukemia (AML) claim 1 , acute promyelocytic leukemia (APL) claim 1 , mixed-lineage leukemia (MLL) claim 1 , myelodysplastic syndrome (MDS) claim 1 , and/or chronic myeloid leukemia (CML).5. The method according to claim 4 , wherein the hematological cancer comprises AML.6. The method according to claim 1 , wherein the subject has been treated or is being treated for a hematological cancer characterized by differentiation arrest.7. The method according to ...

Подробнее
28-09-2021 дата публикации

2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of DHODH

Номер: US0011130745B2

The present invention provides triazolone compounds of general formula (I):in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.

Подробнее
27-10-2020 дата публикации

2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of DHODH

Номер: US0010815215B2

The present invention provides triazolone compounds of general formula (I): in which R1, R2, R3, R4and R5are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.

Подробнее
20-01-2022 дата публикации

COMPOUNDS AND METHODS USEFUL FOR TREATING OR PREVENTING HEMATOLOGICAL CANCERS

Номер: US20220016106A1

The present invention includes methods of treating patients with acute myeloid leukemia across a range of genetic subtypes with DHODH inhibitors, such as 6-fluoro-2-(2′-fluoro-[1,1′-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid).

Подробнее
10-10-2019 дата публикации

METHODS OF TREATMENT WITH A 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONE

Номер: US20190307728A1
Принадлежит:

The present invention provides a method of treating a mutant IDH cancer in a subject comprising administering to a subject in need thereof a therapeutically effective amount of Compound (I): 2. The method of where the mutant IDH cancer is characterized by a mutation in an IDH gene or in an IDH protein.3. The method of further comprising detecting DHO.4. The method of further comprising detecting the presence of a mutant IDH gene or protein.5. The method of claim 4 , wherein the IDH mutant is characterized by a mutation in an IDH-1 gene or in an IDH-1 protein.6. The method of claim 5 , wherein the IDH-1 mutation is an amino acid substitution selected from the group G27D claim 5 , R132C claim 5 , R132G claim 5 , R132H claim 5 , R132L and R132S.7. The method of claim 4 , wherein the the IDH mutant is characterized by a mutation in an IDH-2 gene or in an IDH-2 protein.8. The method of claim 7 , wherein the IDH-2 mutation is an amino acid substitution selected from the group R140L claim 7 , R140W claim 7 , R140Q claim 7 , R172G and R172K.9. The method of claim 1 , wherein a combination of a mutant IDH inhibitor and Compound (I) is administered.10. The method of claim 1 , wherein the cancer is selected from the group consisting of acute myeloid leukemia claim 1 , brain cancer claim 1 , breast cancer claim 1 , colorectal carcinoma claim 1 , gastric cancer claim 1 , gliosarcoma claim 1 , head & neck cancer claim 1 , hepatocellular carcinoma claim 1 , leukemia claim 1 , lung cancer claim 1 , lymphoma claim 1 , multiple myeloma claim 1 , neuroblastoma claim 1 , ovarian cancer claim 1 , pancreatic cancer claim 1 , prostate cancer claim 1 , renal cell carcinoma claim 1 , and sarcoma.11. The method of claim 10 , wherein the lymphoma is selected from the group AIDS-related lymphoma claim 10 , chronic lymphocytic lymphoma (CLL) claim 10 , non-Hodgkin's lymphoma (NHL) claim 10 , T-non-Hodgkin lymphoma (T-NHL) claim 10 , subtypes of NHL such as Diffuse Large Cell Lymphoma (DLBCL) ...

Подробнее
24-08-2021 дата публикации

Compounds and methods useful for treating or preventing hematological cancers

Номер: US0011096934B2

The present invention includes methods of treating patients with acute myeloid leukemia across a range of genetic subtypes with DHODH inhibitors, such as 6-fluoro-2-(2′-fluoro-[1,1′-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid).

Подробнее
23-04-2020 дата публикации

2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONES USEFUL AS INHIBITORS OF DHODH

Номер: US20200123129A1
Принадлежит:

The present invention provides triazolone compounds of general formula (I): in which R, R, R, Rand Rare as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients. 2. The compound of formula (I)in which{'sup': '1', 'claim-text': [{'sub': 5', '8, 'a C-C-alkyl group,'}, {'sub': 2', '8, 'a C-C-haloalkyl group,'}, {'sub': 4', '8, 'claim-text': {'sup': 7', '8, 'claim-text': wherein said phenyl substituent is optionally substituted, one, two or three times, each substituent independently selected from a halogen atom or a group selected from', {'sub': 1', '3', '1', '4', '1', '3, 'C-C-alkyl, C-C-haloalkyl, C-C-alkoxy and hydroxy,'}], 'wherein said cycloalkyl groups are optionally substituted, one or two times, each substituent independently selected from a halogen atom or a group selected from hydroxy, phenyl and —N(R)(R),'}, 'a C-C-cycloalkyl group,'}, {'sub': 1', '6', '3', '8, 'a C-C-alkyl group which is substituted with a C-C-cycloalkyl group,'}, {'sub': 2', '6, 'a C-C-alkyl group which is substituted with a cyano group, a hydroxy group or a phenyl group,'}, {'sub': 3', '6, 'a C-C-alkyl group which is substituted with a monocyclic- or bicyclic heteroaryl group,'}, {'sub': 2', '6', '2', '6, 'a (C-C-hydroxyalkyl)-O—(C-C-alky)- group,'}, {'sub': 3', '6, 'sup': 7', '8, 'a —(C-C-alkyl)-N(R)(R) group,'}, {'sub': 3', '8, 'sup': 7', '8, 'a —(C-C-cycloalkyl)-N(R)(R) group,'}, {'sub': 3', '6, 'sup': 7', '8, 'a —(C-C-alkyl)-C(═O)N(R)(R) group,'}, which is optionally substituted one or two times, each substituent independently selected from a group selected from', {'sub': 1', '3', '1', '4', '1', '6', '3', '6', '2', '1', '6, ' ...

Подробнее
23-04-2020 дата публикации

THIAZOLE COMPOUNDS USEFUL AS PRMT5 INHIBITORS

Номер: US20200123147A1
Принадлежит:

The present invention provides PRMT5 inhibiting compounds of general formula (I): A compound of general formula (I), 6. The compound according to which is selected from the group consisting of:2-[(4-Chlorophenyl)amino]-N-(5-phenyl-1H-pyrazol-3-yl)-1,3-thiazole-4-carboxamide,N-(5-tert-Butyl-1,2-oxazol-3-yl)-2-(pyridin-2-ylamino)-1,3-thiazole-4-carboxamide,N-(5-tert-Butyl-1,2-oxazol-3-yl)-2-(phenylamino)-1,3-thiazole-4-carboxamide,N-(5-tert-Butyl-1,2-oxazol-3-yl)-2-[(4-chlorophenyl)amino]-1,3-thiazole-4-carboxamide,2-[(4-Chlorophenyl)amino]-N-(3-cyclopropyl-1H-pyrazol-5-yl)-1,3-thiazole-4-carboxamide,N-(5-tert-Butyl-1,2-oxazol-3-yl)-2-[(5-fluoropyridin-2-yl)amino]-1,3-thiazole-4-carboxamide,N-(5-tert-Butyl-1,2-oxazol-3-yl)-2-[(4-fluorophenyl)amino]-1,3-thiazole-4-carboxamide,N-(1,3-Benzothiazol-2-yl)-2-[(4-chlorophenyl)amino]-1,3-thiazole-4-carboxamide,2-[(4-Chlorophenyl)amino]-N-(5-methoxy-1H-benzimidazol-2-yl)-1,3-thiazole-4-carboxamide,N-[1-Methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]-2-(phenylamino)-1,3-thiazole-4-carboxamide,2-[(4-Chlorophenyl)amino]-N-(1,3-thiazol-2-yl)-1,3-thiazole-4-carboxamide,N-(5-tert-Butyl-1H-pyrazol-3-yl)-2-[(4-chlorophenyl)amino]-1,3-thiazole-4-carboxamide,N-(5-tert-Butyl-1,2-oxazol-3-yl)-2-[(4-nitrophenyl)amino]-1,3-thiazole-4-carboxamide,N-(3-Cyclopropyl-1H-pyrazol-5-yl)-2-(phenylamino)-1,3-thiazole-4-carboxamide,2-[(4-Chlorophenyl)amino]-N-(1-ethyl-1H-pyrazol-3-yl)-1,3-thiazole-4-carboxamide,N-(5-tert-Butyl-1H-pyrazol-3-yl)-2-(phenylamino)-1,3-thiazole-4-carboxamide,2-[(4-Chlorophenyl)amino]-N-[4-(3,4-dihydroisoquinolin-2(1H)-yl)butyl]-1,3-thiazole-4-carboxamide,N-(5-tert-Butyl-1,2-oxazol-3-yl)-2-[(3-chloro-4-methylphenyl)amino]-1,3-thiazole-4-carboxamide,2-[(4-Chlorophenyl)amino]-N-(1,2-oxazol-3-yl)-1,3-thiazole-4-carboxamide,2-[(4-Chlorophenyl)amino]-N-(5-methyl-1,2-oxazol-3-yl)-1,3-thiazole-4-carboxamide,N-(5-tert-Butyl-1,2-oxazol-3-yl)-2-[(3,4-dichlorophenyl)amino]-1,3-thiazole-4-carboxamide,N-{2-[2-(Diethylamino)ethoxy]-4′- ...

Подробнее
24-06-2021 дата публикации

2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONES USEFUL AS INHIBITORS OF DHODH

Номер: US20210188805A9
Принадлежит:

The present invention provides triazolone compounds of general formula (I): 2. The method according to in which{'sup': '1', 'claim-text': [{'sub': 5', '8, 'a C-C-alkyl group,'}, {'sub': 2', '5, 'a C-C-haloalkyl group,'}, {'sub': 4', '5, 'claim-text': {'sup': 7', '8, 'claim-text': {'sub': 1', '3', '1', '4', '1', '3, 'wherein said phenyl substituent is optionally substituted, one, two or three times, each substituent independently selected from a halogen atom or a group selected from C-C-alkyl, C-C-haloalkyl, C-C-alkoxy and hydroxy,'}, 'wherein said cycloalkyl groups are optionally substituted, one or two times, each substituent independently selected from a halogen atom or a group selected from hydroxy, phenyl and —N(R)(R),'}, 'a C-C-cycloalkyl group,'}, {'sub': 1', '6', '3', '5, 'a C-C-alkyl group which is substituted with a C-C-cycloalkyl group,'}, {'sub': 2', '6, 'a C-C-alkyl group which is substituted with a cyano group, a hydroxy group or a phenyl group,'}, {'sub': 3', '6, 'a C-C-alkyl group which is substituted with a monocyclic- or bicyclic heteroaryl group,'}, {'sub': 2', '6', '2', '6, 'a (C-C-hydroxyalkyl)-O—(C-C-alky)-group,'}, {'sub': 3', '6, 'sup': 7', '8, 'a —(C-C-alkyl)-N(R)(R) group,'}, {'sub': 3', '5, 'sup': 7', '8, 'a —(C-C-cycloalkyl)-N(R)(R) group,'}, {'sub': 3', '6, 'sup': 7', '8, 'a —(C-C-alkyl)-C(═O)N(R)(R) group,'}, [{'sub': 1', '3', '1', '4', '1', '6', '3', '6', '2', '1', '6, 'claim-text': 'wherein said 5- to 6-membered heteroaryl substituent is optionally substituted, one, two or three times, each substituent independently selected from a halogen atom or a group selected from', 'which is optionally substituted one or two times, each substituent independently selected from a group selected from C-C-alkyl, 5- to 6-membered heteroaryl, —C(═O)O(C-C-alkyl), —C(═O)(C-C-alkyl), —C(═O)(C-C-cycloalkyl), —S(═O)(C-C-alkyl) and oxo (═O),'}, {'sub': 1', '3', '1', '4', '1', '3, 'C-C-alkyl, C-C-haloalkyl, C-C-alkoxy and hydroxy,'}, 'and wherein said- to 7- ...

Подробнее
24-06-2021 дата публикации

4,5-annulated 1,2,4-triazolones

Номер: US20210188846A1

The present invention provides triazolone compounds of general formula (I):in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.

Подробнее
03-12-2020 дата публикации

2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONES USEFUL AS INHIBITORS OF DHODH

Номер: US20200377472A1
Принадлежит:

The present invention provides triazolone compounds of general formula (I): 2. The method according to in which{'sup': '1', 'claim-text': [{'sub': 5', '8, 'a C-C-alkyl group,'}, {'sub': 2', '5, 'a C-C-haloalkyl group,'}, {'sub': 4', '5, 'claim-text': {'sup': 7', '8, 'claim-text': {'sub': 1', '3', '1', '4', '1', '3, 'wherein said phenyl substituent is optionally substituted, one, two or three times, each substituent independently selected from a halogen atom or a group selected from C-C-alkyl, C-C-haloalkyl, C-C-alkoxy and hydroxy,'}, 'wherein said cycloalkyl groups are optionally substituted, one or two times, each substituent independently selected from a halogen atom or a group selected from hydroxy, phenyl and —N(R)(R),'}, 'a C-C-cycloalkyl group,'}, {'sub': 1', '6', '3', '5, 'a C-C-alkyl group which is substituted with a C-C-cycloalkyl group,'}, {'sub': 2', '6, 'a C-C-alkyl group which is substituted with a cyano group, a hydroxy group or a phenyl group,'}, {'sub': 3', '6, 'a C-C-alkyl group which is substituted with a monocyclic- or bicyclic heteroaryl group,'}, {'sub': 2', '6', '2', '6, 'a (C-C-hydroxyalkyl)-O—(C-C-alky)-group,'}, {'sub': 3', '6, 'sup': 7', '8, 'a —(C-C-alkyl)-N(R)(R) group,'}, {'sub': 3', '5, 'sup': 7', '8, 'a —(C-C-cycloalkyl)-N(R)(R) group,'}, {'sub': 3', '6, 'sup': 7', '8, 'a —(C-C-alkyl)-C(═O)N(R)(R) group,'}, [{'sub': 1', '3', '1', '4', '1', '6', '3', '6', '2', '1', '6, 'claim-text': 'wherein said 5- to 6-membered heteroaryl substituent is optionally substituted, one, two or three times, each substituent independently selected from a halogen atom or a group selected from', 'which is optionally substituted one or two times, each substituent independently selected from a group selected from C-C-alkyl, 5- to 6-membered heteroaryl, —C(═O)O(C-C-alkyl), —C(═O)(C-C-alkyl), —C(═O)(C-C-cycloalkyl), —S(═O)(C-C-alkyl) and oxo (═O),'}, {'sub': 1', '3', '1', '4', '1', '3, 'C-C-alkyl, C-C-haloalkyl, C-C-alkoxy and hydroxy,'}, 'and wherein said- to 7- ...

Подробнее
12-12-2019 дата публикации

4,5-annulated 1,2,4-triazolones

Номер: US20190375747A1

The present invention provides triazolone compounds compounds of general formula (I): in which R 1 , R 2 , R 3 , R 4 and R 5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.

Подробнее
25-04-2019 дата публикации

2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh

Номер: JOP20190094A1

ABSTRACT The present invention provides triazolone compounds compounds of general formula (I) : (I), in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.

Подробнее
11-07-2018 дата публикации

Compounds and methods useful for treating or preventing hematological cancers

Номер: EP3344243A1

The present invention includes methods of treating patients with acute myeloid leukemia across a range of genetic subtypes with DHODH inhibitors, such as 6-fluoro-2-(2'-fluoro-[1,1'- biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid).

Подробнее
03-05-2018 дата публикации

2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh

Номер: CA3041643A1

The present invention provides triazolone compounds compounds of general formula (I) : in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.

Подробнее
13-01-2022 дата публикации

COMPOUNDS DERIVED FROM 1,2,4-TRIAZOLONES 2,4,5-TRISUBSTITUTED

Номер: CU24572B1

<p>La presente invención proporciona compuestos derivados de 1,2,4-triazolonas 2,4,5-trisustituidas que son inhibidores de la dihidroorotato deshidrogenasa (DHODH) útiles para el tratamiento o prevención de trastornos hiperproliferativos e inflamatorios que poseen la fórmula general (I):</p> <p>ESPACIO PARA FÓRMULA</p> <p>en donde R1, R2, R3, R4 y R5 son como se definen en las presentes reivindicaciones, también se proveen métodos de preparación de dichos compuestos, y compuesto intermedio útiles para preparar dichos compuestos de fórmula (I).</p> <p> </p> <p>The present invention provides compounds derived from 2,4,5-trisubstituted 1,2,4-triazolones that are inhibitors of dihydroorotate dehydrogenase (DHODH) useful for the treatment or prevention of hyperproliferative and inflammatory disorders that have the general formula (I):</p> <p>SPACE FOR FORMULA</p> <p>wherein R1, R2, R3, R4 and R5 are as defined in the present claims, methods of preparing said compounds are also provided , and intermediate compounds useful for preparing said compounds of formula (I).</p> <p> </p>

Подробнее
17-10-2023 дата публикации

Compounds and methods useful for treating or preventing hematological cancers

Номер: CA2996632C

The present invention includes methods of treating patients with acute myeloid leukemia across a range of genetic subtypes with DHODH inhibitors, such as 6-fluoro-2-(2'fluoro[1,1'- biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid).

Подробнее
17-10-2023 дата публикации

4,5-annulated 1,2,4-triazolones

Номер: US11787797B2

The present invention provides triazolone compounds of general formula (I):in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.

Подробнее
28-09-2023 дата публикации

Dosing schedule for a method of treatment with dhodh inhibitors

Номер: US20230301969A1
Автор: Andreas Janzer
Принадлежит: Bayer AG

The present invention provides N-(2-chloro-6-fluorophenyl)-4-[4-ethyl-3-(hydroxymethyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-5-fluoro-2-{[(2S)-1,1,1-trifluoropropan-2-yl]oxy}benzamide for use in a method of cancer treatment using a dose schedule of daily dosing on equal to 4 days up to 5 days followed by a short off period of equal to 2 days up to 3 days, as well as a method of treatment of cancer diseases with a composition comprising said DHODH inhibitor using the new dosing schedule.

Подробнее
16-11-2023 дата публикации

2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh

Номер: US20230365524A1

The present invention provides triazolone compounds of general formula (I): in which R 1 , R 2 , R 3 , R 4 , and R 5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and prophylaxis of diseases, in particular hyperproliferative disorders, as a sole agent or in combination with other active ingredients.

Подробнее
05-07-2023 дата публикации

Dosing schedule for a method of treatment with dhodh inhibitors

Номер: EP4203951A1
Автор: Andreas Janzer
Принадлежит: Bayer AG

The present invention provides N-(2-chloro-6-fluorophenyl)-4-[4-ethyl-3-(hydroxymethyl)-5-oxo- 4,5-dihydro-1 H-1,2,4-triazol-1-yl]-5-fluoro-2-{[(2S)-1,1,1-trifluoropropan-2-yl]oxy}benzamide for use in a method of cancer treatment using a dose schedule of daily dosing on equal to 4 days up to 5 days followed by a short off period of equal to 2 days up to 3 days, as well as a method of treatment of cancer diseases with a composition comprising said DHODH inhibitor using the new dosing schedule.

Подробнее
03-03-2022 дата публикации

Dosing schedule for a method of treatment with dhodh inhibitors

Номер: WO2022043288A1
Автор: Andreas Janzer
Принадлежит: Bayer Aktiengesellschaft

The present invention provides N-(2-chloro-6-fluorophenyl)-4-[4-ethyl-3-(hydroxymethyl)-5-oxo- 4,5-dihydro-1 H-1,2,4-triazol-1-yl]-5-fluoro-2-{[(2S)-1,1,1-trifluoropropan-2-yl]oxy}benzamide for use in a method of cancer treatment using a dose schedule of daily dosing on equal to 4 days up to 5 days followed by a short off period of equal to 2 days up to 3 days, as well as a method of treatment of cancer diseases with a composition comprising said DHODH inhibitor using the new dosing schedule.

Подробнее